Scientists hunt for clues in aggressive brain cancer
NCT ID NCT03526822
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 100 adults with newly diagnosed glioblastoma, the most common and aggressive brain tumor. Researchers will measure certain proteins (MMP2 and MMP9) in blood and tumor tissue, and compare them with MRI scans. The goal is to better understand how these proteins relate to tumor growth and treatment response, which could help guide future therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2018
- Expected to finish
-
Jan 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient, male or female, aged 18 years or over * Imaging suggestive of glioblastoma * Patient eligible for excision surgery (partial, subtotal or macroscopically complete) * Candidate for concomitant and adjuvant radiotherapy chemotherapy (Stupp protocol) * Patient having signed an informed consent * Patient having undergone a preoperative MRI Exclusion Criteria: * Existence of a contraindication to the MRI * Nonoperable lesion * History of radiotherapy and / or chemotherapy for this lesion * Scalability of a low grade lesion * Person in emergency situation, a legal person of legal age (guardianship, guardianship or legal guardianship), or unable to express his or her consent * No affiliation to a social security scheme (beneficiary or beneficiary) * Pregnant or lactating woman
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Brain tumor are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Assistance Publique Hôpitaux de Marseille
RECRUITINGMarseille, 13354, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a trio of repurposed drugs shrink recurrent brain tumors?
- Can an existing drug boost bevacizumab against recurrent brain cancer?
- One extra radiation dose after standard brain cancer therapy: can it boost the immune system?
- Radioactive tracer lights up Oxygen-Starved brain tumors
- Can a common virus vaccine help fight brain cancer?
- Radioactive tiles target brain tumors in frail patients